Andre Luiz Oliveira da Silva

Andre Luiz Oliveira da Silva

Auto-generated profile, based on publicly available information

Andre Luiz Oliveira da Silva

Agência Nacional de Vigilância Sanitária

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2019 in Tobacco Control
Verified
Journal Article
Closed access
PDF file
ASAndre Luiz Oliveira da Silva
Andre Luiz Oliveira da Silva
SBStella Aguinaga Bialous
Stella Aguinaga Bialous
PAPatrícia Gonçalves Duarte Albertassi
Patrícia Gonçalves Duarte Albertassi
DADaniela Aparecida dos Reis Arquete
Daniela Aparecida dos Reis Arquete
AFAna Marcia Messeder Sebrao Fernandes
Ana Marcia Messeder Sebrao Fernandes
JMJosino Costa Moreira
Josino Costa Moreira
Background The tobacco industry (TI) uses several strategies to attract new consumers, including using additives in tobacco products, which makes tobacco especially attractive to youth. Based on scientific evidence and the principles of the WHO Framework Convention on Tobacco Control, the Brazilian Health Regulatory Agency (ANVISA, for the name in Portuguese), published the Collegiate Board Resolution (RDC, for the name in Portuguese) 14/2012 in 2012, prohibiting the addition of substances that enhance the flavour and taste of tobacco products in order to make them more attractive. In response, the TI used various strategies to prevent RDC 14/2012 from entering into force. At the time, the Brazilian additive ban was the most comprehensive in the world as it included a ban on menthol. Objectives This paper analyses the arguments and strategies used by the TI to prevent the implementation of the additives ban. Methods Review of published articles, reports, legislation and legislative activity, internal TI documents, media stories and other documents to describe TI’s reaction to the ban. Results The results show that the TI used some well-known strategies to delay or cancel the entering into force of the resolution. For example, the TI attempted political interference, used litigation and commissioned studies with findings that questioned the resolution’s rationale. The TI strategies used in Brazil are similar to those used at the global level to oppose other tobacco control measures. Conclusions TI successfully delayed the most comprehensive additive ban in the world using its usual tactics, despite the fact that none of the arguments presented by the TI had an acceptable scientific basis or evidence.

1 January 2020 in Cadernos de Saude Publica
Verified
Journal Article
Open access
PDF file
ASAndre Luiz Oliveira da Silva
Andre Luiz Oliveira da Silva
JMJosino Costa Moreira
Josino Costa Moreira
SMStella Regina Martins
Stella Regina Martins
Entre os fatores de risco para desfechos mais graves como a necessidade de internação em unidade de terapia intensiva (UTI) e/ou uso de ventilação mecânica e morte para a COVID-19 estão: idade de 65 anos ou mais; pessoas internadas em instituições de longa permanência; pacientes com doença pulmonar obstrutiva crônica, asma (moderada a grave) e dependentes de oxigênio; pessoas com problemas cardíacos graves ou descompensados; hipertensos descompensados; diabéticos; portadores de doenças cromossômicas ou estado de fragilidade imunológica; indivíduos com insuficiência renal crônica avançada; gestantes de alto risco; pessoas de qualquer idade com obesidade grave (IMC > 40); e condições médicas, como doenças hepáticas 2,3. É possível ainda que a COVID-19 seja uma doença endotelial, podendo levar a quadros graves de coagulopatias e tromboses 4.

1 August 2019 in Ciencia & Saude Coletiva
Verified
Journal Article
Open access
ASAndré Luiz Oliveira da Silva
André Luiz Oliveira da Silva
JMJosino Costa Moreira
Josino Costa Moreira
Resumo O Brasil foi um dos primeiros países do mundo a proibir os Dispositivos Eletrônicos de Fumar (DEFs), tal proibição foi motivada pela inexistência de evidências relativas às alegadas propriedades terapêuticas e da inocuidade destes produtos. Por conta de tal proibição, A Anvisa foi criticada, especialmente de grupos de usuários. Estes grupos argumentam que tal ação proibiu um produto que auxiliaria a cessação ao tabagismo e seria menos tóxico que os cigarros comuns. Assim sendo, surge o questionamento se esta decisão foi acertada ou não. Os dados disponíveis mostram que os DEFs possuem formulações diversas e algumas substâncias tóxicas são liberadas durante sua utilização em níveis significativos. Estudos em animais e em humanos demonstraram potencial efeito tóxico. Os DEFs também demostraram que podem afetar a saúde de fumantes passivos. Quanto a seu uso como ferramenta de cessação, os estudos ainda não são conclusivos. Observou-se também um alto grau de uso entre adolescentes em países que seu uso foi autorizado. Desta forma o Brasil ao proibir estes produtos, impediu que a população consumisse um produto sem comprovação que auxiliasse no tratamento do tabagismo, com indícios de significativa toxidade e altamente atrativo aos jovens.

17 February 2026 in Public Health Reports®
Verified
Journal Article
Closed access
SGStanton Glantz
Stanton Glantz
ASAndre Luiz Oliveira da Silva
Andre Luiz Oliveira da Silva
Objective: Electronic cigarettes (e-cigarettes) are often presented as a less harmful alternative to combustible cigarettes (hereinafter, cigarettes). This study updates an earlier meta-analysis of 107 population studies of e-cigarette disease risks. Methods: We pooled data from studies in PubMed, EMBASE, Web of Science, and PsychINFO from January 1, 2005, through January 1, 2025, in a random-effects meta-analysis if we identified ≥5 studies for a disease outcome. Results: We identified 142 odds ratios (ORs) (107 [75%] from cross-sectional studies and 35 [25%] from longitudinal studies) from 124 articles, including 18 new articles. Comparing e-cigarette use with cigarette use, the ORs (95% CIs) for metabolic dysfunction (1.00 [0.91-1.09]) and oral disease (0.89 [0.78-1.02]) were not different from 1.0. The ORs (95% CIs) for cardiovascular disease (0.76 [0.58-0.99]), stroke (0.62 [0.47-0.82]), asthma (0.84 [0.74-0.95]), chronic obstructive pulmonary disease (0.55 [0.40-0.76]), and fetal growth (0.64 [0.44-0.92]) were ≤1.0. Pooled ORs for dual use versus cigarette use were increased for all outcomes (range, 1.22-1.42) except fetal growth (0.99). Pooled ORs for e-cigarette use, compared with nonuse of e-cigarettes, were increased for all outcomes (e-cigarette range, 1.24-1.53) except fetal growth (1.20). Dual use was associated with increased ORs for all outcomes (1.49-3.17). Studies had a low risk of bias. Results were generally not sensitive to study characteristics. Confidence in conclusions was mostly moderate to high except for stroke, where confidence was low for some outcomes, and fetal growth, for which confidence was very low for all outcomes. Conclusion: The growing literature increases confidence that e-cigarette use is associated with disease outcomes indistinguishable from or approaching cigarette use, with dual use associated with higher ORs. E-cigarettes should not be promoted as a safer alternative to cigarettes.

1 January 2019 in Cadernos de Saude Publica
Verified
Journal Article
Open access
PDF file
ASAndre Luiz Oliveira da Silva
Andre Luiz Oliveira da Silva
JMJosino Costa Moreira
Josino Costa Moreira
Essa ação foi parte da resposta da agência reguladora americana ao que pode ser considerada uma epidemia do uso de dispositivos eletrônicos para fumar entre estudantes dos níveis Médio e Fundamental nos Estados Unidos. Dentre os estudantes do nível Médio o uso de cigarros eletrônicos aumentou de 1,5% em 2011 para 20,8 % em 2018, sendo 2017 o ano do aumento mais significativo 2. Entre os estudantes do Ensino Fundamental o uso desses produtos saltou de 0,6% em 2011 para 4,9% em 2018 2. Em resumo, praticamente 1 em cada 5 estudantes americanos do Ensino Médio usa cigarros eletrônicos, em sua maioria produtos com diversos sabores e majoritariamente da marca Juul 2. Esse significativo aumento observado em 2017 estaria associado à popularização dessa marca no mercado americano 2.

14 October 2024 in Tobacco Control
Verified
Journal Article
Open access
PDF file
ASAndre Luiz Oliveira da Silva
Andre Luiz Oliveira da Silva
SBStella Bialous
Stella Bialous
Introduction Product design is a key tobacco industry strategy to recruit consumers and hinder cessation. An important technology in tobacco product design is the use of additives including those that create characterising flavours, that is, flavours that are perceived by taste and or smell by the user. To curb youth use, many countries are implementing policies to limit the use of flavours and other additives in tobacco products. This paper reviews the global landscape of tobacco additives policies including those focusing only on flavouring additives, updating a previous review. Methods We gathered additives policy data from available online sources of tobacco control policies including parties’ reports to the WHO Framework Convention on Tobacco Control (where WHO refers to World Health Organization), the website Tobacco Control Laws, government websites, searches with the Google search engine and consultations with the WHO to ensure comprehensiveness of the assessment. The policies were classified according to their objective and characteristics: Labelling regulations, sales bans and tobacco product design regulations. We classified and organised the regulations according to their stated intent. Results We found that 62 countries had tobacco products’ additives-related regulations at the regional, national or subnational levels. Most of these regulations focused on flavouring additives especially bans on the selling, importing and manufacturing tobacco products with characterising flavours. Conclusions The data demonstrate various global policies addressing additives and/or flavours and a range of definitions of additives and flavours. Establishing common definitions and standards could facilitate cooperation between countries and regions.